Back to News
Market Impact: 0.3
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
Source: globenewswire.com
Healthcare & Biotech
The primary endpoint of progression-free survival (PFS) was not met, but the key secondary endpoint of overall survival (OS) improved with VAZKEPA/VASCEPA. The text provides no effect size, statistical details, or timing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.05
More News
- Xencor reports phase 1 data for cancer drug XmAb819
- ArriVent reports phase 1 data for cancer drug ARR-217
- Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
- UK immigration crackdown threatens £15 billion care sector
- US Midterm Elections 2026: Key Issues, From Affordability to AI
- Billy Evans’ ‘Theranos 2.0’ startup has patents, investors, and a missing CTO—but no product